Stock data
Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of US$74.68M and net income of -US$644.76M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$74.68M | — | -US$648.13M | -US$644.76M | — |
| 2024 | US$58.84M | — | -US$479.00M | -US$463.66M | — |
| 2023 | US$44.58M | — | -US$350.06M | -US$328.07M | — |
| 2022 | US$39.84M | — | -US$245.73M | -US$239.48M | — |
| 2021 | US$10.18M | — | -US$182.78M | -US$186.48M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$7.67M | -US$131.00M | — |
| 2026-03-31 | US$6.47M | -US$117.50M | — |
| 2025-12-31 | US$35.54M | -US$108.12M | — |
| 2025-09-30 | US$5.17M | -US$162.25M | — |
| 2025-06-30 | US$19.22M | -US$171.90M | — |
| 2025-03-31 | US$14.74M | -US$202.49M | — |
| 2024-12-31 | US$4.55M | -US$178.91M | — |
| 2024-09-30 | US$26.08M | -US$95.84M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.